Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Sammy Saab; Sarah H. Park; Masashi Mizokami; Masao Omata; Alessandra Mangia; Ed Eggleton; Yanni Zhu; Steven J. Knox; Phil Pang; Mani Subramanian; Kris Kowdley; Nezam H. Afdhal

doi:10.1002/hep.28425

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

Original language	English
Journal	Hepatology
DOIs	https://doi.org/10.1002/hep.28425
Publication status	Accepted/In press - 2016

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.28425

Cite this

@article{b9eadfefe4634707b19a7a6b65404f48,

title = "Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older",

abstract = "Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of ",

author = "Sammy Saab and Park, {Sarah H.} and Masashi Mizokami and Masao Omata and Alessandra Mangia and Ed Eggleton and Yanni Zhu and Knox, {Steven J.} and Phil Pang and Mani Subramanian and Kris Kowdley and Afdhal, {Nezam H.}",

year = "2016",

doi = "10.1002/hep.28425",

language = "English",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

AU - Saab, Sammy

AU - Park, Sarah H.

AU - Mizokami, Masashi

AU - Omata, Masao

AU - Mangia, Alessandra

AU - Eggleton, Ed

AU - Zhu, Yanni

AU - Knox, Steven J.

AU - Pang, Phil

AU - Subramanian, Mani

AU - Kowdley, Kris

AU - Afdhal, Nezam H.

PY - 2016

Y1 - 2016

N2 - Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

AB - Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of

UR - http://www.scopus.com/inward/record.url?scp=84959235497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959235497&partnerID=8YFLogxK

U2 - 10.1002/hep.28425

DO - 10.1002/hep.28425

M3 - Article

C2 - 26704693

AN - SCOPUS:84959235497

SN - 0270-9139

JO - Hepatology

JF - Hepatology

ER -

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this